KIT and breast adenocarcinoma: In this regard, Samoszuk and Corwin showed that when imatinib mesylate (Gleevec) was used to inhibit tyrosine kinase activity, including c-kit, there was an acceleration in the growth rate of mammary adenocarcinomas in mice while the number of mast cells was similar in both treated and untreated animals [22].